Other languages GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Real-time Estimate Cboe BZX Other stock markets 12:23:40 2024-06-27 EDT			5-day change	1st Jan Change
0.291 ^USD	-0.31%		+15.92%	-87.72%

06-04	Transcript : GlycoMimetics, Inc. - Special Call
06-04	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia	06-04
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	05-06
Sector Update: Health Care	05-06
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint	05-06
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia	05-06
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Glycomimetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-27
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687	01-04
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia	01-02
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687	23-09-06
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
GlycoMimetics Says FDA Approves Time-Based Analysis of Overall Survival in Phase 3 Acute Myeloid Leukemia Study	23-06-15
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia	23-06-15
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee	23-02-15
Insider Sell: Glycomimetics	23-01-27
Insider Buy: Glycomimetics	22-12-28
GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting	22-12-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Other languages

Filters